Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy
| Autor: | Steven A. Saenz, Geoffrey O. Gillard, David J. Huss, Jason D. Fontenot |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Multiple Sclerosis Daclizumab Natural killer NK Immunology Clinical Neurology chemical and pharmacologic phenomena Inflammation CD16 Antibodies Monoclonal Humanized Cohort Studies 03 medical and health sciences Antigens CD Immunity medicine Humans Innate lymphoid cell Immunology and Allergy Lymphocytes skin and connective tissue diseases biology Multiple sclerosis Flow Cytometry medicine.disease Killer Cells Natural body regions 030104 developmental biology ILC Neurology Immunoglobulin G Monoclonal biology.protein Female Neurology (clinical) medicine.symptom Antibody Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Neuroimmunology. 294:41-45 |
| ISSN: | 0165-5728 |
| DOI: | 10.1016/j.jneuroim.2016.03.008 |
| Popis: | Innate lymphoid cells (ILCs) play an important role in immunity, inflammation, and tissue remodeling and their dysregulation is implicated in autoimmune and inflammatory disorders. We analyzed the impact of daclizumab, a humanized monoclonal anti-CD25 antibody, on circulating natural killer (NK) cells and ILCs in a cohort of multiple sclerosis patients. An increase in CD56bright NK cells and CD56hiCD16intermediate transitional NK cells was observed. No significant change in total ILCs or major ILC subpopulations was observed. These results refine our understanding of the impact of daclizumab on innate lymphoid cell populations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect